Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment

Hematology/Oncology Clinics of North America

Volumn 17, Issue 1, 2003, Pages 149-176

  Bick, Rodger L ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dallas Thromb Hemostasis Clin Ctr   (United States)

^c ThromboCare Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIFIBRINOLYTIC AGENT; BETA THROMBOGLOBULIN; D DIMER; FIBRINOPEPTIDE; HEMOSTATIC AGENT; MOLECULAR MARKER; PLASMINOGEN ACTIVATOR; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; THROMBOXANE;

BASEMENT MEMBRANE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME INHIBITOR COMPLEX; FIBRIN CLOT; HUMAN; INTRAVASCULAR HEMOLYSIS; LABORATORY DIAGNOSIS; MICROVASCULATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE MEMBRANE;

DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS;

EID: 0037319114     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00102-8     Document Type: Review

References (173)

1. Baker WF. Clinical aspects of disseminated intravascular coagulation: a clinician's point of view. Semin Thromb Hemost 1989;15:1-57.
2. Bick RL, Baker WF. Disseminated intravascular coagulation. Hematol Pathol 1992;6:1-24.
3. Bick RL, Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response. Semin Thromb Hemost 1996;22:69-88.
4. Bick RL. Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin Appl Thromb Hemost 1995;1: 3-23.
5. Bick RL. Disseminated intravascular coagulation and related syndromes: a clinical review. Semin Thromb Hemost 1988;14:299-338.
6. Lasch HG, Henne DL, Huth K, Sandritter W. Pathophysiology, clinical manifestations, and therapy of consumptive coagulopathy, Am J Cardiol 1967;20:381-91.
7. Rodriquez-Erdman F. Bleeding due to increased intravascular blood coagulation: hemorrhagic syndromes caused by consumption of blood-clotting factors (consumption coagulopathies). N Engl J Med 1965;273:1370-8.
8. Dubber AHC, McNicol GP, Douglas AS. Acquired hypofibrino-genemia: the "defibrination syndrome." A study of seven patients. Scott Med J 1967;12: 138-51.
9. Nilsson IM. Local fibrinolysis as a mechanism for haemorrhage. Thromb Diath Haemorh 1975;34:623-33.
10. Steiner PE, Lushbough CC. Maternal pulmonary embolism by amniotic fluid as a cause of shock and unexplained deaths in obstetrics. JAMA 1941;117:1245-54.
11. Hafter R, Graeff H. Molecular aspects of defibrination in a reptilase-treated case of "dead-fetus syndrome." Thromb Res 1975;7:391-9.
12. Steichele DF. Consumptive coagulopathy in obstetrics and gynecology. Thromb Diath Haemorrh 1969;36:177-94.
13. Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia. BMJ 1971;1:12-6.
14. Roberts JM, May WJ. Consumption coagulopathy in severe pre-eclampsia. Obstet Gynecol 1976;48:163-6.
15. Spivack JL, Sprangler DB, Bell WR. Defibrination after intra-amniotic injection of hypertonic saline. N Engl J Med 1972;287:321-3.
16. Egeberg O. Blood coagulation and intravascular hemolysis. Scand J Clin Lab Invest 1962; 14:217-22.
17. Krevins JR, Jackson DP, Cowley CL, Hartman RC. The nature of the hemorrhagic disorder accompanying hemolytic transfusion reactions in man. Blood 1957;12:834-41.
18. Langdell RD, Hedgpeth EM. A study of the role of hemolysis in the hemostatic defect of transfusion reactions. Thromb Diath Haemorrh 1959;3:566-71.
19. Surgenor DM. Erythrocytes and blood coagulation. Thromb Diath Haemorrh 1974;32:247-59.
20. Abildgaard CF, Corrigan JJ, Seeler RA, Simone JV, Schulman I. Meningiococcemia associated with intravascular coagulation. Pediatrics 1967;40:78-83.
21. Corrigan JJ. Changes in the blood coagulation system associated with septicemia. N Engl J Med 1968;279:851-6.
22. McKay DG, Muller-Berghous G. Therapeutic implications of disseminated intravascular coagulation. Am J Cardiol 1967;20:392-410.
23. Yoshikawa T, Tanaka R, Guze LB. Infection and disseminated intravascular coagulation. Medicine (Baltimore) 1971;50:237-58.
24. Cline MJ, Melmon KL, Davis WC, Williams HE. Mechanism of endotoxin interaction with leukocytes. Br J Haematol 1968;15:539-47.
25. Paloma MJ, Paramo JA, Rocha E. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator versus urokinase of PAI generation, fibrin deposits and mortality. Thromb Haemost 1995;74:1578-82.
26. Cronberg S, Skansberg P, Nivenios-Larsson K. Disseminated intravascular coagulation in septicemia caused by beta-hemolytic streptococci. Thromb Res 1973;3:405-12.
27. Rubenberg WL, Baker LR, McBride JA, Sevitt JA, Brain WL. Intravascular coagulation in a case of clostridium perfringens septicemia: treatment by exchange transfusion and heparin. BMJ 1967;3:271-4.
28. Gagel C, Linder M, Muller-berghous G, Lasch H. Virus infection and blood coagulation. Thromb Diath Haemorrh 1970;23:1-11.
29. McKay DG, Margaretten W. Disseminated intravascular coagulation in virus diseases. Arch Intern Med 1967;120:129-52.
30. Stormorken H. Interrelationships between the coagulation, the fibrinolytic and the kallikrein and kinin system. Scand J Hematol 1979;34:24-7.
31. Bick RL. Alterations ofhemostasis in malignancy. In: Bick RL, Bennett JM, Brynes RK, editors. Hematology: clinical and laboratory practice. St. Louis: Mosby; 1993. p. 1583 [chapter 101].
32. Bick RL. Hemostasis in malignancy. In: Bick RL, editor. Disorders of thrombosis and hemostasis: clinical and laboratory practice. Chicago: ASCP Press; 1992. p. 239 [chapter 12].
33. Bick RL. Coagulation abnormalities in malignancy. Semin Thromb Hemost 1992;18:353-72.
34. Bick RL, Laughlin WR. Myeloproliferative syndromes. Lab Med 1993;24:770-6.
35. Bick RL, Strauss JF, Frenkel EP. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996;10:875-907.
36. Brown RC, Campbell D, Thompson J. Increased fibrinolysis with malignant disease. Arch Intern Med 1962;109:128-33.
37. Bick RL. Paroxysmal nocturnal hemoglobinuria and March hemoglobinuria. In: Bick RL, Bennett JM, Brynes RK, editors. Hematology: clinical and laboratory practice. St. Louis: Mosby; 1993. p. 547 [chapter 36].
38. Sheehan KCF, Schneiber RD. The synergy and antagonism of interferon-γ and TNF. In: Beutler B, editor. Tumor necrosis factor: the molecules and their emerging role in medicine. New York: Raven Press; 1992. p. 145-74.
39. Tracy KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
40. Doukas J, Pober JS. IFN-gamma enhances endothelial activation induced by tumor necrosis factor but not IL-1. J Immunol 1990;145:1727-33.
41. Movat HZ, Burrowes CE, Cybulsky MI, Dinanello CA. Acute inflammation and a Schwartzman-like reaction induced by interleukin-1 and tumor necrosis factor: synergistic action of the cytokines in the inducton of inflammation and microvascular injury. Am J Pathol 1987;129: 463-76.
42. Old LJ. Tumor necrosis factor. Science 1985;230:630-2.
43. Old LJ. Tumor necrosis factor. Sci Am 1988;258:59-75.
44. Bouchama A, Hammami M, Haq A, Jackson J, al-Sedairy S. Evidence for endothelial cell activation/injury in heatstroke. Crit Care Med 1996;24:1173-8.
45. Tang GJ. Similarity and synergy of trauma and sepsis: role of tumor necrosis factor-alpha and interleukin-6. Acta Anaesthesiologia Sinica 1996;34:141-9.
46. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 1995;80:519-26.
47. Curreri PW, Wilterdink ME, Baxter CR. Coagulation dynamics following thermal injury: effect of heparin and protamine sulfate. Ann Surg 1975;181:161-3.
48. Saliba MJ, Demsey WL, Kruggel JL. Large bums in humans: treatment with heparin. JAMA 1973;225:261-9.
49. Al-Mondhiry H. Disseminated intravascular coagulation: experience in a major cancer center. Thromb Diath Haemorrh 1975;34:181-93.
50. Aoki N, Moroi M, Matsuda M. The behavior of alpha-2-plasmin inhibitor in fibrinolytic states. J Clin Invest 1977;60:361-9.
51. Bruhn HD, Conard J, Mannucci M, Montaegudo J, Pelzer H, Reverter JC, et al. Multicentric evaluation of a new assay for prothrombin fragment F 1 + 2 determination. Thromb Haemost 1992;68:413-7.
52. Bick RL. Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. In: Walz DA, McCoy LE, editors. Contributions to hemostasis. Ann NY Acad Sci 1981;370:851-4.
53. Inceman S, Tangun Y. Chronic defibrination syndrome due to a giant hemangioma associated with microangiopathic hemolytic anemia. Am J Med 1969;46:997-1002.
54. Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child 1940;59:1063-70.
55. Kaxmier FJ, Didisheim P, Fairbanks VK, Ludwig J, Payne WS, Bowie EJW. Intravascular coagulation and arterial disease. Thromb Diath Haemorrh 1969;36:295-303.
56. Schnetzer GW, Penner JA. Chronic intravascular coagulation syndrome associated with atherosclerotic aortic aneurysm. South Med J 1973;66:264-8.
57. Owen CA, Bowie EJW. Chronic intravascular coagulation fibrinolysis (ICF) syndromes (DIC). Semin Thromb Hemost 1977;3:268-90.
58. Bick RL, Tse N. Hemostasis abnormalities associated with prosthetic devices and organ transplantation. Lab Med 1992;23:462-8.
59. Bick RL. Alterations of hemostasis associated with surgery, cardiopulmonary bypass surgery, and prosthetic devices. In: Ratnoff OD, Forbes C, editors. Disorders of hemostasis. Philadelphia: WB Saunders; 1991, p. 382 [chapter 13].
60. Bick RL. Disseminated intravascular coagulation. Hematol Oncol Clin North Am 1992;6: 1259-86.
61. Stibbe J, Gomes M, de Ouda A. Management of chronic CID: evaluation of separate measurements of fibrin (FbDP) and fibrinogen (FgDP) degradation products concomitant with fibrin monomers [abstract]. Thromb Haemost 1989;62(Suppl 1):373.
62. Mammen EF. Perspectives for the future. Intensive Care Med 1993;1:S29-34.
63. McKay DG, Margaretten W, Csavossy I. An electron microscope study of the effects of bacterial endotoxin on the blood-vascular system. Lab Invest 1966;15:1815-29.
64. Muller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989;15:58-87.
65. Owen CA, Bowie EJW, Cooper HA. Turnover of fibrinogen and platelets in dogs undergoing induced intravascular coagulation. Thromb Res 1973;2:251-9.
66. Latallo ZS. Formation and detection of fibrinogen-derived complexes. Thromb Diath Haemorrh 1975;34:677-85.
67. 2-terminal amino disulfide knot." J Biol Chem 1972;247:4775-81.
68. Marder VJ, Shulman HR, Carroll WR. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physico-chemical and immunological characterization. J Biol Chem 1969;244:2111-9.
69. Bang NU, Chang M. Soluble fibrin complexes. Semin Thromb Hemost 1974;1:91-128.
70. Breen FA, Tullis JZ. Ethanol gelation, a rapid screening test for intravascular coagulation. Ann Intern Med 1968;69:1197-206.
71. Fletcher AP, Alkjaersig N. The proteolysis of fibrinogen by plasmin: the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally. J Lab Clin Med 1966;68:780-802.
72. Gurewich V, Hutchinson E. Detection of intravascular coagulation by protamine sulfate and ethanol gelation tests. Ann Intern Med 1971;75:895-902.
73. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation: clinical and pathophysiological mechanisms and manifestations. Haemostasis 1999;29:111-34.
74. Niewiarowski S, Regoeczi E, Stewart G, Senyi A, Mustard J. Platelet interaction with polymerizing fibrin. J Clin Invest 1972;51:685-700.
75. Stachurska J, Lopaciuk S, Gerdin B, Saldeen T, Koroscik A, Kopec M. Effects of proteolytic degradation products of human fibrinogen and of human factor VIII on platelet aggregation and vascular permeability. Thromb Res 1979;15:663-72.
76. Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation. Am J Hematol 1997;54: 219-24.
77. Ishibashi M, Ito N, Fujita M, Furue H, Yamaji T. Endothelin-1 as an aggravating factor of disseminated intravascular coagulation associated with malignant neoplasms. Cancer 1994; 73:191-5.
78. Ono S, Mochizuki H, Tamakuma S. A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Am J Surg 1996;171:409-15.
79. Robson S, Shephard E, Kirsch R. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994;86:322-6.
80. Elsayed Y, Nakagawa K, Ichikawa K, Ohkawara S, Sueishi K. Expression of tissue factor and interleukin-1 beta in a novel rabbit model of disseminated intravascular coagulation induced by carrageenan and lipopolysaccharide. Pathobiology 1995;63:328-40.
81. Hoffman M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 by two distinct mechanisms. Blood Cells Mol Dis 1995;21:156-67.
82. Okajima K, Fujise R, Motosato Y, Ushijima M, Okabe H, Takatsuki K. Plasma levels of granulocyte elastase-alpha 1-proteinase inhibitor complex in patients with disseminated intravascular coagulation: pathophysiologic implications. Am J Hematol 1994;47:82-8.
83. Stormorken H. Relation of the fibrinolytic to other biological systems. Thromb Diath Haemorrh 1975;34:378-85.
84. Schreiber AD, Austen KF. Interrelationships of the fibrinolytic, coagulation, kinin generation, and complement systems. Semin Hematol 1973;6:593-600.
85. Collins P, Noble K, Reittie J, Hoffbrand A, Pasi K, Yong K. Induction of tumor factor expression in human monocyte/endothelium cocultures. Br J Haematol 1995;91:963-70.
86. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in post-trauma disseminated intravascular coagulation: relationship to multiple organ dysfunction. Crit Care Med 1995;23:1835-42.
87. Bick RL, Murano G. Physiology of hemostasis. In: Bick RL, Bennett JM, Brynes RK, editors. Hematology: clinical and laboratory practice. St. Louis: Mosby; 1993. p. 1285 [chapter 84].
88. Kaplan A, Meier H, Mandel R. The Hageman factor-dependent pathways of coagulation, fibrinolysis, and kinin generation. Semin Thromb Hemost 1976;3:6-26.
89. van Iwaarden F, Bouma B. Role of high molecular weight kininogen in contact activation. Semin Thromb Hemost 1987;13:15-24.
90. Beller FK, Theiss W. Fibrin derivatives, plasma hemoglobin and glomerular fibrin deposition in experimental intra-vascular coagulation. Thromb Diath Haemorrh 1973;29:363-74.
91. McKay DG, Linder MM, Cruse VK. Mechanisms of thrombosis of the microcirculation. Am J Pathol 1971;63:231-54.
92. Robboy SJ, Coleman RW, Minna JD. Pathology of disseminated intravascular coagulation (DIC): analysis of 26 cases. Human Pathol 1972;3:327-43.
93. Muller-Berghous G. Pathophysiology of generalized intravascular coagulation. Semin Thromb Hemost 1977;3:209-46.
94. Owen CA, Bowie EJW. Chronic intravascular syndromes. Mayo Clin Proc 1974;49:673-9.
95. Skjorten F. Hyaline microthrombi in an autopsy material: a quantitative study with discussion of the relationship to small vessel thrombosis. Acta Pathol Microbiol Scand 1969;76:361-75.
96. Bleyl U. Morphologic diagnosis of disseminated intravascular coagulation: histologic, histochemical, and electron-microscopic studies. Semin Thromb Hemost 1977;3:247-67.
97. Bick RL, Murano G. Physiology of hemostasis. Clin Lab Med 1994;14:677-708.
98. Bleyl U, Kuhn W, Graeff H. Reticulo-endotheliale clearance intravascaler: fibrinmonere in der milz. Thromb Diath Haemorrh 1969;22:87-100.
99. Boyd JF. Disseminated fibrin-thromboembolism among neonates dying within 48 hours of birth. Arch Dis Child 1967;42:401-9.
100. Bull B, Kuhn IN. The production of schistocytes by fibrin strands (a scanning electron microscope study). Blood 1970;35:104-11.
101. Bull B, Rubenberg M, Dacie J, Brain MC. Microangiopathic hemolytic anemia: mechanisms of red-cell fragmentation. Br J Haematol 1968;14:643-52.
102. Heyes H, Kohle W, Slijerpcevic B. The appearance of schistocytes in the peripheral blood in correlation to degree of disseminated intravascular coagulation. Haemostasis 1976;5:66-73.
103. Slaastad RA, Godal NC. Coagulation profile and ethanol gelation test with special reference to components consumed during coagulation. Scand J Haematol 1976;16:25-32.
104. Bick RL. Platelet defects. In: Disorders of hemostasis and thrombosis: principles of clinical practice. New York: Thieme; 1985. p. 65 [chapter 4].
105. Eckhardt T, Muller-Berghous G. The role of blood platelets in the precipitation of soluble fibrin endotoxin. Scand J Haematol 1975;14:181-9.
106. Karpatkin S. Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood 1978;51:307-16.
107. Blaisdell FW, Stallone RJ. The mechanism of pulmonary damage following traumatic shock. Surg Gynecol Obstet 1970;130:15-22.
108. Bleyl U. Comparative studies in adults and newborn infants on the pathogenesis of pulmonary hyaline membranes. Verh Dtsch Ges Pathol 1970;54:340-8.
109. Martin AM, Soloway HB, Simmons RL. Pathologic anatomy of the lungs following shock and trauma. J Trauma 1968;8:687-99.
110. Soloway HB, Castillo Y, Martin AM. Adult hyaline membrane disease. Ann Surg 1968;168: 937-45.
111. Hardaway RM, Adams WH. Blood clotting problems in acute care. Acute Care 1989;14: 138-207.
112. Hardaway RM, Dixon RS, Foster EF, Karabin BL, Scifres FD, Meyers T. The effect of hemorrhagic shock on disseminated intravascular coagulation. Ann Surg 1976;184:43-5.
113. Muller-Berghous G, Mann B. Precipitation of ancrod-induced soluble fibrin by aprotinin and norepinephrine. Thromb Res 1973;2:305-22.
114. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response. Semin Thromb Hemost 1996;22:69-88.
115. Bick RL, Fekete LF, Wilson WL. Treatment of disseminated intravascular coagulation with antithrombin 111. Trans Am Soc Hematol 1976;167.
116. Bick RL. Clinical hemostasis practice: the major impact of laboratory automation. Semin Thromb Hemost 1983;9:139-71.
117. Fareed J. New methods in hemostatic testing. In: Fareed J, Messmore HL, Fenton J, Brinkhous KM, editors. Perspectives in hemostasis. New York: Pergamon Press; 1981. p. 310.
118. Messmore HL. Automation in coagulation testing: clinical applications. Semin Thromb Hemost 1983;9:335-9.
119. Bick RL. Disseminated intravascular coagulation: clinical/laboratory correlations [abstract]. Am J Clin Pathol 1982;77:244.
120. Bick RL. Disseminated intravascular coagulation: objective laboratory diagnostic criteria and guidelines for management. Clin Lab Med 1994;14:729-68.
121. Marder VJ, Matchett MO, Sherry S. Detection of serum fibrinogen and fibrin degradation products: comparison of six techniques using purified products and application in clinical studies. Am J Med 1971;51:71-82.
122. Thomas DP, Niewiarowski S, Myers AR, Bloch KJ, Coleman RW. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med 1970;283:663-8.
123. Gurewich V, Lipinsky B. Semiquantitative determination of soluble fibrin monomer complexes by chromatography and serial dilution protamine sulfate test. Am J Clin Pathol 1976; 65:397-401.
124. Hedner U, Nilsson IM. Parallel determinations of FDP and fibrin monomers with various methods. Thromb Diath Haemorrh 1972;28:268-79.
125. Sonnabend D, Cooper D, Fiddes P, Penny R. Fibrin degradation products in thromboembolic disease. Pathology 1972;4:47-51.
126. Kidder WR, Logan LJ, Rapaport SI, Patch MJ. The plasma protamine paracoagulation test: clinical and laboratory evaluation. Am J Clin Pathol 1972;58:675-86.
127. Francis CW, Marder VJ. A molecular model of plasmic degradation of cross-linked fibrin. Semin Thromb Hemost 1982;8:25-35.
128. Plow EF, Edgington TS. Surface markers of fibrinogen and its physiologic derivatives related by antibody probes. Semin Thromb Hemost 1982;8:36-56.
129. Matsumoto T, Nishijima Y, Teramura Y, Fujino K, Hibino M, Hirata M. Monoclonal antibodies to fibrinogen-fibrin degradation products which contain D-domain. Thromb Res 1985; 38:297-302.
130. Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983;31:767-78.
131. Bick RL, Baker W. Diagnostic efficacy of the D-dimer assay in DIC and related disorders. Thromb Res 1992;65:785-90.
132. Bick RL. Disseminated intravascular coagulation. In: Brubaker DB, Simpson MB, editors. Dynamics of hemostasis and thrombosis. Bethesda (MD): American Association of Blood Banks; 1995. p. 133 [chapter 8].
133. Lane DA, Preston FE, Van Ross ME, Kakkar VV. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol 1978;40:609-15.
134. Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, et al. Measurement of cross-linked fibrin degradation products: an immunoassay using monoclonal antibodies. Thromb Haemost 1983;50:591-4.
135. Elias A, Aptel I, Huc B, Chale J, Nguyen F, Cambus J, et al. D-dimer test and diagnosis of deep vein thrombosis: a comparative study of 7 assays. Thromb Haemost 1996;76:518-22.
136. Ellis DR, Eaton AS, Plank MC, Butman BT, Ebert RF. A comparative evaluation of ELISA's for D-Dimer and related fibrin(ogen) degradation products. Blood Coagul Fibrinolysis 1993;4:537-49.
137. Charles L, Edwards T, Macik B. Evaluation of sensitivity and specificity of six D-dimer latex assays. Arch Pathol Lab Med 1994;118:1102-5.
138. Murano G. The molecular structure of fibrinogen. Semin Thromb Hemost 1974;1:1-32.
139. Rosenberg JS, Beeler DL, Rosenberg RD. Activation of human prothrombin by highly purified human factors Vand Xa in the presence of human antithrombin. J Biol Chem 1975;250:1607-17.
140. 1+2 fragment and thrombin-antithrombin complex. Blood 1982;59:1086-97.
141. Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-dimers, thrombin antithrombin complexes and prothrombin fragments 1 + 2: diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991;65:28-31.
142. Ceriello A, Giacomello R, Colatutto A, Taboga C, Gonano F. Increased prothrombin fragment 1 + 2 in Type 1 diabetic patients. Haemostasis 1992;22:50-1.
143. Demers C, Ginsberg JS, Henderson P, Ofosu FA, Weitz JI, Blajchman MA. Measurements of markers of activated coagulation in antithrombin III deficient patients. Thromb Haemost 1992;67:542-4.
144. Okamoto K, Takaki A, Takeda S, Katoh H, Ohsato K. Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: determination of prothrombin fragment 1 + 2 and other markers. Haemostasis 1992;22:17-24.
145. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153-9.
146. Sorensen JV, Jensen HP, Rahr HR, Borris L, Lassen MR, Knudsen F. F 1 + 2 and FPA in urine from patients with multiple trauma and healthy individuals: a pilot study. Thromb Res 1992;67:429-34.
147. Carville DG, Dimitrijevec N, Walsh M, Digirolamo T, Brill EM, Drew N, et al. Thrombus precursor protein: marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 1996;42:1537-41.
148. Laurino JP, Pelletier TF, Eadry R, Kouavis A. Thrombus precursor protein and the measurement of thrombosis in patients with acute chest pain syndrome. Ann Clin Lab Sci 1997; 27:338-45.
149. Bick RL, Dukes ML, Wilson WL, Fekete L. Antithrombin III (AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res 1977;10:721-30.
150. Okajima K. Clinical relevance of determination of plasma AT-III and alpha 2 PI activities in patients with DIC: applications of the molecular markers for the pathophysiology of DIC. Japanese Journal of Clinical Pathology 1994;42:45-55.
151. Bick RL, McClain BJ. A clinical comparison of chromogenic, fluorometric, and natural (fibrinogen) substrates for determination of antithrombin-III [abstract]. Thromb Haemost 1981; 46:364.
152. Fareed J, Messmore HL, Walenga JM, Bermes EW, Bick RL. Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemost 1982;8:288-301.
153. Asakura H, Saito M, Ito K, Jokaji Y, Uotani C, Kumabashiri I, et al. Levels of thrombinantithrombin III complex in plasma in cases of acute promyelocytic leukemia. Thromb Res 1988;50:895-900.
154. Cronlund M, Hardin J, Burton J, Lee L, Haber I, Bloch KJ. Fibrinopeptide-A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosis. J Clin Invest 1976;58:142-51.
155. Douglas JT, Shah M, Lowe GDO, Prentice CRM. Fibrinopeptide-A and Beta-thromboglobulin levels in pre-eclampsia and hypertensive pregnancy. Thromb Haemost 1982;47:54-5.
156. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans: normative aging study. J Clin Invest 1987;80:1527-34.
157. Fareed J, Bick RL, Squillaci G, Walenga J, Messmore HL, Bermes EW. Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders [abstract]. Clin Chem 1983;29:1641-58.
158. Walenga JM, Fareed J, Mariani G, Mesmore HL, Bick RL, Emanuele RM. Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. Semin Thromb Hemost 1984;10:252-63.
159. Banez El, Triplett DA, Harms C. A clinical study on the use of a fluorogenic substrate assay of plasminogen. Thromb Res 1983;31:845-53.
160. Clavin SA, Bobbitt JL, Shuman RT, Smithwick EL. Use of peptidyl-4-methoxy-2-naphthylamides to assay plasmin. Anal Biochem 1977;80:355-65.
161. Harpel PC. Alpha-2-plasmin inhibitor and alpha-2-macroglobulin-plasmin complexes in plasma. J Clin Invest 1981;68:46-55.
162. Menon IS. A study of the possible correlation of euglobulin lysis time and dilute blood clot lysis time in the determination of fibrinolytic activity. Lab Pract 1968;17:334-5.
163. Menon IS, Martin A, Weightman D. Estimation of euglobulin lysis time using a time-saving recorder. Lab Pract 1969;18:1186-7.
164. Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 1979;53:313-24.
165. Takahashi H, Koike T, Yoshida N, Kitahara O, Hanono M, Hibata A, et al. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha-2 plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 1986;23:153-66.
166. Wiman B, Jacobsson L, Andersson M, Mellbring G. Determination of plasmin-alpha-2-plasmin inhibitor complex in plasma samples by means ofa radioimmunoassay. Scand J Clin Lab Invest 1983;43:27-33.
167. Takahashi H, Hanano M, Takizawa S, Tatewaki W, Shibata A. Plasmin-alpha-2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am J Hematol 1988;28:162-6.
168. Matsuda T, Seki T, Ogawara M, Miura R, Yokouchi M, Murakami M. Levels of beta-thromboglobulin and platelet factor 4 in various diseases. Acta Hematologica Japonica 1980;43:871-8.
169. Zahavi J, Kakkar VV. B-thromboglobulin: a specific marker of in vivo platelet release reaction. Thromb Haemost 1980;44:23-9.
170. Bick RL. Clinical implications of molecular markers in hemostasis and thrombosis. Semin Thromb Hemost 1984;10:290-3.
171. Bick RL. Disseminated intravascular coagulation: objective criteria for diagnosis and management. Med Clin North Am 1994;78:511-44.
172. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998;24:3-18.
173. Kwaan HC. Disseminated intravascular coagulation. Med Clin N Am 1972;56:177-91.